SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegatio ...

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Vestis Corporation (NYSE: VSTS) securities between May 2, 2024, and May 6, 2025, alleging that the company misled investors regarding its customer growth and strategic initiatives [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Vestis Corporation failed to disclose its inability to execute planned strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and revenue [2]. - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue guidance for the full fiscal year, and provided third-quarter guidance significantly below market expectations, attributing poor results to "lost business in excess of new business" and "lower adds over stops" [3]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file a motion by August 8, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders are not required to participate in the case to be eligible for recovery and can remain absent class members if they choose not to take action [4].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Financial Impact - Following the release of a report by Spruce Point Capital Management that highlighted various red flags regarding Tempus' management and operations, the stock price fell by $12.67, or 19.23%, from $65.87 to $53.20 per share on May 28, 2025 [3][4]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action against Tempus AI, with options to serve as lead plaintiff or remain an absent class member [5].

Core Viewpoint - A class action lawsuit has been filed against Civitas Resources, Inc. for allegedly misleading investors about its production capabilities and financial condition during the specified class period [1][2]. Allegations - Civitas is accused of failing to disclose significant reductions in oil production expected in 2025 due to declines after a production peak in Q4 2024 and a low TIL count at the end of 2024 [2]. - The company would need to acquire additional acreage and development locations to increase oil production, which would incur significant debt and potentially require selling corporate assets [2]. - Financial conditions would necessitate disruptive cost-reduction measures, including a significant workforce reduction [2]. - The company's business and financial prospects, as well as operational capabilities, were allegedly overstated [2]. Stock Price Impact - Following the revelation of these issues on February 24, 2025, Civitas's stock price dropped by $8.95 per share, representing a decline of over 18%, closing at $40.35 per share on February 25, 2025 [2]. Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by July 1, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Company Background - Civitas Resources, Inc. is an independent exploration and production company focused on crude oil and liquids-rich natural gas in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [1].

Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides biopharmaceutical product and medical device development solutions [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and operates under several transition services agreements with Labcorp [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA trajectories for 2025 were not in line with prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [3]. - The company indicated that its pre-spin projects were late in their life cycle, resulting in lower revenue and profitability than expected for 2025 [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting transition services agreements [4]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, which misrepresented the viability of its post-spin business model and financial prospects [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities during the specified period, alleging that the company misled investors regarding its production capacity and the value of its contracts [1][2]. Allegations - The complaint asserts that Red Cat Holdings failed to disclose that the production capacity of its Salt Lake City Facility was overstated and that the value of the U.S. Army's Short Range Reconnaissance Program (SRR) Contract was also exaggerated [2]. - Kerrisdale Capital's report indicated that the SRR Contract was valued between $20 million and $25 million, contrary to Red Cat's claims, and raised concerns about misleading information regarding the Salt Lake City Facility's production capacity [3]. Stock Impact - Following the release of Kerrisdale Capital's report on January 16, 2025, Red Cat's stock price dropped by $2.35 per share, representing a decline of 21.54%, closing at $8.56 per share on January 17, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action have until July 22, 2025, to apply for this status, although participation is not required to be eligible for recovery [4]. Company Background - Robbins LLP has been recognized for its efforts in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action has been filed against Krispy Kreme, Inc. for allegedly misleading investors regarding its partnership with McDonald's, which has led to a significant decline in the company's financial performance and stock price [1][2]. Group 1: Allegations and Financial Performance - The complaint alleges that Krispy Kreme did not disclose a material decline in demand for its products at McDonald's locations following the initial marketing launch [1]. - It is claimed that the declining demand at McDonald's contributed to a decrease in average sales per door per week [1]. - The partnership with McDonald's was reportedly not profitable, posing risks to its continuation and leading to a pause in expansion into new McDonald's locations [1]. - Krispy Kreme's first quarter 2025 financial results showed net revenue of $375.2 million, a decline of 15.3%, and a net loss of $33.4 million compared to a prior year net loss of $6.7 million [2]. - Following the financial results announcement, Krispy Kreme's stock price fell by nearly 25%, negatively impacting investors [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 15, 2025 [3]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. - The firm has a history of advocating for shareholder rights and holding company executives accountable since 2002 [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly failing to disclose the impact of Medicaid redetermination on its business prospects, leading to significant financial misrepresentation [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Elevance Health misled investors by stating that they were monitoring Medicaid cost trends and that premium rates were sufficient to manage risks, despite rising Medicaid expenses [2]. - The company allegedly failed to disclose that the Medicaid redetermination process was resulting in a higher acuity and utilization of its Medicaid members, which was not reflected in their financial guidance for 2024 [2]. - Following the revelation of increased utilization expectations in the Medicaid sector, Elevance's stock price dropped by $32.21 per share, or 5.8%, indicating a significant market reaction to the disclosed information [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 11, 2025, to serve as lead plaintiff, representing the interests of other class members [4]. - Shareholders are not required to participate in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the law firm handling the case, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].